Priorix-tetra™; Priorix™; Varilrix™
Проводит ГлаксоСмитКляйн ЛЛС
Страница компанииStudy in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00226499/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- В исследовании участвуют здоровые добровольцы.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 11 мес. — 1.8 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 5803 чел. во всех странах исследования.
- Плановая дата окончания (10.2006) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 14
Критерии включения
- Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol for the whole duration of the study.
- Male or female subject between 12 and 22 months of age at the time of the first vaccination.
- Subjects free of obvious health problems, as established by medical history and physical examination before entering the study.
- Written informed consent obtained from the parents/guardians of the subject after they have been informed on the risks and benefits of the study, in a language they clearly understand and before performance of any study procedure.
- Subjects whose parents/guardians have direct access to telephone/mobile phone.
- Subjects:
- with at least one sibling (with negative history of varicella disease/vaccination) at home, or
- attending day care center, or
- attending childminders, i.e. someone taking care of several children, or
- who are in contact for at least once a week with other children without a known positive history of varicella disease/vaccination, while playing in close physical contact for more than 5 minutes.
Критерии невключения
- Previous vaccination against measles, mumps, rubella and/or varicella.
- History of previous measles, mumps, rubella and/or varicella/ herpes zoster diseases.
- Known exposure to measles, mumps, rubella and/or varicella/herpes zoster within 30 days prior to the start of the study.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- Administration of immunoglobulins and/or any blood products within three months prior to the first vaccine dose or planned administration during the study period.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical.
- Family history of congenital or hereditary immunodeficiency.
- History of allergic diseases or reactions likely to be exacerbated by any component of the vaccines, including systemic allergy to egg proteins or neomycin.
- Major congenital defects or serious chronic illness.
- Residence in the same household as newborns (0-4 weeks of age), pregnant women who are varicella-susceptible, persons with a known immunodeficiency or any other persons at high risk for varicella.
- History of any neurologic disorders or seizures.
- Use of any investigational or non-registered product (drug/vaccine other than the study vaccines) within 14 days prior to vaccination and planned use during the study period.
- Additional exclusion criteria for subjects included in the subset:
- \- Administration of a licensed vaccine within 14 days prior to vaccination and planned use until approximately 42 days after the last study vaccine dose (Day 84) with the exception of oral polio vaccine (OPV).
Источник: ClinicalTrials.gov, NCT00226499 · запись обновлена в реестре 23 сентября 2019.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 36
- Phase A: Number of Subjects With Confirmed Varicella Case — From 42 days post dose 2 until the end of Phase A
Цель исследования
An observer-blind study to evaluate GlaxoSmithKline Biologicals' live attenuated varicella vaccine and GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella vaccine in the prevention of varicella disease in children. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00226499 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.